Search PubMed⌕ Search

Biomedical subjects

E Coeugniet

Publications and source records attributed to E Coeugniet.

At least 19 recordsLinked to original sources
PubMed2006

[Early preventive pressure therapy in extensive skin grafts on children's face, a comeback of classic methods? A retrospective study on 8 cases].

INTRODUCTION: One of the common techniques in the treatment of giant facial naevi is the excision covered by a skin graft. It's functional and esthetic results are not always excellent. Physiotherapy including immediate postsurgical preventive pressure therapy could ameliorate these results and shorten the period of scarring. PURPOSE: Evaluation of scarring results with early pressure therapy in skin grafts of congenital facial naevi. PATIENTS AND METHODS: Retrospective study on 8 children being 1 to 9 years old and presenting congenital facial naevi. All of them were treated by excision followed by full thickness skin grafting. The associated physiotherapy was realized by a transparent rigid or elastic mask. The pressure was started after skin graft uncovering between 7 and 20 days. The period for this treatment was depending on the maturing of the scar. Evaluation was established by 3 examinators on: time till scar maturing, trame quality and esthetic quality. RESULTS: The period till definitive scar maturing was showed to be between 8 and 14 month; trame quality was mostly evaluated as excellent, the esthetic result oscillated between good and medium. CONCLUSION: Physiotherapy seems to be an essential association for the treatment of facial full thickness skin grafts in children. Early pressure therapy could better the functional and esthetic result and accelerate scar maturing. Simple skin grafting could become the first treating option in this indication. Future prospective studies are expected to confirm these results.

Child↗
PubMed2002

[Prospective study of early predictive factors of permanent hypocalcemia after bilateral thyroidectomy].

AIM OF THE STUDY: The aim of this prospective cohort study was to identify the early criteria potentially predictive for outcome of permanent hypocalcemia after thyroidectomy. PATIENTS AND METHODS: Serum calcium (Ca) et phosphorus (Ph) were measured daily until discharge in 2035 consecutive patients undergoing bilateral thyroidectomy. In all patients experiencing postoperative hypocalcemia, defined as a Ca < 8.0 mg/dl on two consecutive days, parathyroid hormone was measured prior initiation of calcium therapy et discharge (early PTH), et blood sample was also obtained 7 to 14 days after discharge for Ca et Ph measurements (delayed Ca et Ph). These patients were then followed up until complete resolution of hypocalcemia or at least one year. Those still needing substitutive therapy to maintain normocalcemia one year after surgery were considered to have permanent hypocalcemia. Correlation of outcome with clinical characteristics, postoperative Ca et Ph levels, early PTH, et delayed Ca et Ph were examined with univariate analysis et multivariate logistic regression. RESULTS: Postoperative hypocalcemia occurred in 153 patients (7.5%) and spontaneously recovered in all but 7 patients (0.3%). Delayed Ca, and delayed Ph were found to be predictive for outcome of hypocalcemia by univariate analysis (p < 0.01). Relative risk to develop permanent hypocalcemia was 15 for patients with early PTH < 12 pg/ml, 52 when delayed Ph was > 4.0 mg/dl, and 121 when delayed Ca was < 8.0 mg/dl. None of the 113 patients with delayed Ca > or = 8.0 mg/dl and delayed Ph < or = 4.0 mg/dl developed permanent hypocalcemia, in contrast to 1 out of 31 patients (3%) with delayed Ca > 8.0 mg/dl or delayed Ph > 4.0 mg/dl, and 6 out of 9 patients (66%) with delayed Ca < 8.0 mg/dl and delayed Ph > 4.0 mg/dl. Both delayed Ca and delayed Ph appeared as independent factors predicting outcome of hypocalcemia at one year with multivariate logistic regression analysis. CONCLUSION: Delayed serum calcium and phosphorus levels, when measured one week after starting calcium therapy but prior to administration of any vitamin D analogs, accurately predict outcome of hypocalcemia after thyroidectomy. Patients with delayed Ca under 8.0 mg/dl and/or delayed Ph above 4.0 mg/dl are at high risk to develop permanent hypocalcemia.

Adult↗
PubMed1978

Human leucocyte response to migration inhibitory activity from lymphocytes. Modification by aprotinin, Tranexamic acid and phenylmethyl sulfonylfluoride.

Human lymphokines can elicit several effects associated with inflammation, e.g. leucocyte migration inhibition and fibrinolysis. These effects can be assessed in vitro by the leucocyte migration agarose technique (LMAT) and the leucocyte migration fibrinolysis technique (LMFT). The present study shows that preincubation of normal leucocytes with aprotinin, tranexamic acid and phenyl-methyl-sulfonylfluoride (PMSF) reduces or abolishes their migration inhibition response to leucocyte migration inhibition factor. The compounds exert this effect at non-toxic concentrations, which do not otherwise interfere with migration or fibrinolysis, and are non-toxic as estimated by PHA stimulation of lymphocytes. The LMFT is more sensitive to the modifying effect than the LMAT. The effect of aprotinin and tranexamic acid is reversible, the effect of PMSF is irreversible.

Aprotinin↗
PubMed1977

Leucocyte migration inhibitory activity of concanavalin-A-stimulated lymphocytes. In vivo and in vitro modifications with dipyridamole and acetylsalicylic acid.

Lymphocytes from 14 patients treated with a combination of acetylsalicylic acid (ASA) and dipyridamole (DIPY) showed a decreased ability to produce leucocyte migration inhibitory activity (LMIA) when stimulated with concanavalin-A (ConA). The combined treatment also produced a decrease of leucocyte response to a standard LMIA-containing culture supernatant. Treatment with only one of the two drugs did not cause detectable alteration of the lymphocyte response to Con-A or the leucocyte response to LMIA. In vitro, both DIPY and ASA were independently effective in decreasing the LMIA production of Con-A-stimulated lymphocytes and the leucocyte response to a standard LMIA-containing culture supernatant.

Adult↗
PubMed1976

Leucocyte migration fibrinolysis technique (LMFT): description of a method.

Human leucocytes can migrate in a gel medium consisting of fibrin, 10% horse serum and tissue culture medium 199. The cells migrate within the fibrin gel mass. The 24 h. areas of migration depend upon the volume and concentration of the cell suspension applied on the fibrin gel. The amount of cells per mm2 migration culture area is less than half the amount used in the leucocyte migration agarose test. The results are reproducible, the standard variation of the migration areas is below 10%. The method is potentially useful for several purposes such as for measuring fibrinolytic and migratory activity of granulocytes, monocytes and lymphocytes and modification of these functions by lymphokines.

Cell Movement↗
PubMed1976

Leucocyte migration inhibitory activity of concanavalin-A-stimulated human lymphocytes. Modification by dipyridamole, lysine-acetylsalicylate and heparin.

The in vitro effects of heparin, dipyridamole (DIPY) and lysine-acetylsalicylate (LASA) on human peripheral blood leucocyte migration and upon production/release and effect of leucocyte migration inhibitory activity (LMIA) from lymphocytes stimulated with concanavalin-A (con-A) have been studied. The final concentration of each drug was of the same order of magnitude as during clinical treatment. The leucocyte migration under agarose was significantly increased by DIPY at a concentration of 100 mug/ml. The release/production of LMIA was inhibited by DIPY at 1 mug/ml and by LASA at 0.3 mug/ml. Heparin had no influence on LMIA release, even at 10 IU/ml. The LMIA of supernatants from con-A-stimulated lymphocyte cultures was inhibited by DIPY at a concentration of 10 mug/ml, by LASA at 3 mug/ml and by heparin at 10 IU/ml. The findings suggest that DIPY and LASA could have a dual role as modifiers of inflammation: 1) the well known role as antiaggregants tending to limit and impede thrombosis, and 2) as antagonists to the lymphocyte-mediated (type IV) immune reaction through a depressive action on lymphokine production/release and activity.

Aspirin↗
PubMed1976

Lymphokines and thrombosis. II. Procoagulant activity produced by human lymphocytes stimulated with concanavalin A (con-A).

Human lymphocytes stimulated with concanavalin-A produce a coagulant activity which decreases the clotting time as expressed through the recalcification time of citrated plasma, the partial thromboplastin time, the thrombin clotting time of citrated plasma and the thrombin clotting time of fibrinogen solutions. The culture supernatants of human lymphocytes stimulated with concanavalin-A also have a direct coagulant effect on human fibrinogen solution. They decrease the lag period of recalcification time of citrated plasma but do not modify the duration of polymerization as measured with a spectrophotometric method.

Blood Coagulation↗
PubMed1976

Leucocyte migration inhibitory activity (LMIA) on concanavalin A (Con-A) stimulated human lymphocytes. Comparison of leucocyte migration capillary technique (LMCT), leucocyte migration agarose technique (LMAT), and leucocyte migration fibrinolysis technique (LMFT).

Leucocyte migration and migration inhibition in fibrin medium may reveal new aspects of lymphokine activity associated with immunological inflammation. Leucocyte migration fibrinolysis technique is compared with the leucocyte migration capillary technique and the leucocyte migration agarose technique. In the present model experiment the three methods gave comparable results. The leucocyte migration fibrinolysis technique involves a new principle for detection of lymphokines and can probably be developed to give more exact information about the interrelationship between thrombosis, fibrinolysis and lymphokines.

Adult↗
PubMed1976

Lymphokines and thrombosis. I. Thrombocyte aggregating activity released by human lymphocytes stimulated with concanavalin-A.

Supernatants from Con-A stimulated human lymphocytes containing leucocyte migration inhibitory activity were measured for thrombocyte aggregation activity and for influence on thrombocyte rich plasma clot retraction and whole blood clot retraction. The lymphocyte released activity of the supernatants produced thrombocyte aggregation and an acceleration of clot retraction. The activity resisted heating at 56 degrees C for 30 min and was inactivated at 80 degrees C for 30 min. The active substance seems to have a molecular weight above 10,000 daltons. The findings suggest that thrombotic processes associated with cell-mediated (type IV) immune inflammation could be due, at least partially, to lymphokine effects on thrombocytes.

Blood Platelets↗